{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:36:05Z","timestamp":1772120165159,"version":"3.50.1"},"reference-count":48,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2018,10,25]]},"DOI":"10.1253\/circj.cj-18-0506","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T22:35:19Z","timestamp":1536618919000},"page":"2872-2879","source":"Crossref","is-referenced-by-count":25,"title":["Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke"],"prefix":"10.1253","volume":"82","author":[{"given":"Shinichi","family":"Wada","sequence":"first","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okata","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Divion of Clinical Chemistry, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Science, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>N Engl J Med<\/i> 2011; 365: 883\u2013891.","DOI":"10.1056\/NEJMoa1009638"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. <i>Circ J<\/i> 2012; 76: 2104\u20132111.","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2011; 365: 981\u2013992.","DOI":"10.1056\/NEJMoa1107039"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2013; 369: 2093\u20132104.","DOI":"10.1056\/NEJMoa1310907"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban \u2013 an oral, direct factor Xa inhibitor \u2013 in patients undergoing major orthopaedic surgery. <i>Clin Pharmacokinet<\/i> 2008; 47: 203\u2013216.","DOI":"10.2165\/00003088-200847030-00006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. <i>Thromb Haemost<\/i> 2012; 107: 379\u2013387.","DOI":"10.1160\/TH11-06-0391"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM. Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. <i>Thromb Res<\/i> 2012; 130: 956\u2013966.","DOI":"10.1016\/j.thromres.2012.09.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. <i>Thromb Haemost<\/i> 2014; 111: 808\u2013816.","DOI":"10.1160\/TH13-09-0741"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. <i>J Am Coll Cardiol<\/i> 2014; 64: 1128\u20131139.","DOI":"10.1016\/j.jacc.2014.05.065"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. <i>Hematology Am Soc Hematol Educ Program<\/i> 2015; 2015: 117\u2013124.","DOI":"10.1182\/asheducation.V2015.1.117.3916182"},{"key":"11","unstructured":"11. Samama MM, Amiral J, Guinet C, Le Flem L, Seghatchian J. Monitoring plasma levels of factor Xa inhibitors: How, why and when? <i>Expert Rev Hematol<\/i> 2013; 6: 155\u2013164."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Barton J, Wong A, Graudins A. Anti-Xa activity in apixaban overdose: Case report. <i>Clin Toxicol<\/i> 2016; 54: 871\u2013873.","DOI":"10.1080\/15563650.2016.1204453"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. <i>J Arrhythm<\/i> 2016; 32: 42\u201350.","DOI":"10.1016\/j.joa.2015.08.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Seiffge DJ, Kagi G, Michel P, Fischer U, Bejot Y, Wegener S, et al. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. <i>Ann Neurol<\/i> 2018; 83: 451\u2013459.","DOI":"10.1002\/ana.25165"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kanemoto M, Kuhara H, Ueda T, Shinohara T, Oda T, Nakao F, et al. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation. <i>Circ J<\/i> 2014; 78: 2651\u20132656.","DOI":"10.1253\/circj.CJ-14-0512"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. <i>Thromb Haemost<\/i> 2010; 104: 1263\u20131271.","DOI":"10.1160\/TH10-05-0328"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: Suitability of three anti-Xa assays: A multicentre French GEHT study. <i>Thromb Haemost<\/i> 2014; 111: 240\u2013248.","DOI":"10.1160\/TH13-06-0470"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet<\/i> 2015; 385: 2288\u20132295.","DOI":"10.1016\/S0140-6736(14)61943-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sakaguchi T, Osanai H, Murase Y, Ishii H, Nakashima Y, Asano H, et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. <i>J Cardiol<\/i> 2017; 70: 244\u2013249.","DOI":"10.1016\/j.jjcc.2016.11.013"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Osanai H, Ajioka M, Masutomi T, Kuwayama T, Ishihama S, Sakamato Y, et al. Measurement of anti-factor Xa activity in patients on apixaban for non-valvular atrial fibrillation. <i>Circ J<\/i> 2015; 79: 2584\u20132590.","DOI":"10.1253\/circj.CJ-15-0470"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shin H, Cho MC, Kim RB, Kim CH, Choi NC, Kim SK, et al. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation. <i>J Thromb Thrombolysis<\/i> 2018; 45: 250\u2013256.","DOI":"10.1007\/s11239-017-1590-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sato S, Uehara T, Ohara T, Suzuki R, Toyoda K, Minematsu K, et al. Factors associated with unfavorable outcome in minor ischemic stroke. <i>Neurology<\/i> 2014; 83: 174\u2013181.","DOI":"10.1212\/WNL.0000000000000572"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sakamoto Y, Koga M, Kimura K, Nagatsuka K, Okuda S, Kario K, et al. Intravenous thrombolysis for patients with reverse magnetic resonance angiography and diffusion-weighted imaging mismatch: SAMURAI and NCVC rt-PA Registries. <i>Eur J Neurol<\/i> 2014; 21: 419\u2013426.","DOI":"10.1111\/ene.12308"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: The Japan standard stroke registry study. <i>Cerebrovasc Dis<\/i> 2007; 24: 289\u2013295.","DOI":"10.1159\/000105682"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. <i>JAMA<\/i> 2001; 285: 2864\u20132870.","DOI":"10.1001\/jama.285.22.2864"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. <i>BMJ<\/i> 2011; 342: d124.","DOI":"10.1136\/bmj.d124"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. <i>Chest<\/i> 2010; 138: 1093\u20131100.","DOI":"10.1378\/chest.10-0134"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <i>Nephron<\/i> 1976; 16: 31\u201341.","DOI":"10.1159\/000180580"},{"key":"29","unstructured":"29. Xarelto [package insert]. Bayer Schering Pharma AG, 2013."},{"key":"30","unstructured":"30. Eliquis [package insert]. Pfizer AG, 2013."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. <i>Int J Clin Pharmacol Ther<\/i> 2014; 52: 564\u2013573.","DOI":"10.5414\/CP201967"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban: An oral, direct factor Xa inhibitor. <i>Thromb Haemost<\/i> 2010; 103: 815\u2013825.","DOI":"10.1160\/TH09-03-0176"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>J Thromb Haemost<\/i> 2005; 3: 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: Insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>J Am Coll Cardiol<\/i> 2014; 63: 891\u2013900.","DOI":"10.1016\/j.jacc.2013.11.013"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, et al. Three month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. <i>Int J Stroke<\/i> 2016; 11: 565\u2013574.","DOI":"10.1177\/1747493016632239"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. <i>Can J Cardiol<\/i> 2013; 29: S24\u2013S33.","DOI":"10.1016\/j.cjca.2013.04.002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, Mueck W. Confirmation of model-based dose selection for a Japanese phase III Study or rivaroxaban in non-valvular atrial fibrillation patients. <i>Drug Metab Pharmacokinet<\/i> 2013; 28: 321\u2013331.","DOI":"10.2133\/dmpk.DMPK-12-RG-109"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. <i>Clin Pharmacokinet<\/i> 2014; 53: 1\u201316.","DOI":"10.1007\/s40262-013-0100-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Okata T, Toyoda K, Okamoto A, Miyata T, Nagatsuka K, Minematsu K. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. <i>PLoS One<\/i> 2014; 9: e113641.","DOI":"10.1371\/journal.pone.0113641"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: A subgroup analysis of a randomized trial. <i>Ann Intern Med<\/i> 2013; 158: 861\u2013868.","DOI":"10.7326\/0003-4819-158-12-201306180-00003"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>Eur Heart J<\/i> 2016; 37: 1145\u20131153.","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation: Meta-analysis. <i>Circ J<\/i> 2015; 79: 339\u2013345.","DOI":"10.1253\/circj.CJ-14-1042"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: A subgroup analysis of the J-ROCKET AF trial. <i>J Stroke Cerebrovasc Dis<\/i> 2014; 23: 379\u2013383.","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.021"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Deguchi I, Tanahashi N, Takao M. Timing of treatment initiation with oral anticoagulant for acute ischemic stroke in patients with nonvalvular atrial fibrillation. <i>Circ J<\/i> 2017; 81: 180\u2013184.","DOI":"10.1253\/circj.CJ-16-0923"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Gioia LC, Kate M, Sivakumar L, Hussain D, Kalashyan H, Buck B, et al. Early rivaroxaban use after cardioembolic stroke may not result in hemorrhagic transformation: A prospective magnetic resonance imaging study. <i>Stroke<\/i> 2016; 47: 1917\u20131919.","DOI":"10.1161\/STROKEAHA.116.013491"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P, et al. Early start of DOAC after ischemic stroke: Risk of intracranial haemorrhage and recurrent events. <i>Neurology<\/i> 2016; 87: 1856\u20131862.","DOI":"10.1212\/WNL.0000000000003283"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thromb Res<\/i> 2016; 137: 178\u2013183.","DOI":"10.1016\/j.thromres.2015.12.001"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: A randomized crossover study. <i>J Thromb Haemost<\/i> 2017; 15: 2017\u20132028.","DOI":"10.1111\/jth.13801"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/11\/82_CJ-18-0506\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T01:31:18Z","timestamp":1571880678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/11\/82_CJ-18-0506\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-0506","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}